The management of cancer is constantly evolving through the introduction of new advances related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care.
The NCCN 2021 Virtual Congress: Hematologic Malignancies™ will focus on updates to the NCCN Guidelines, new, emerging and novel therapeutic agents, advances in cancer care, and the practical management of patients with hematologic malignancies.
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with HER2-positive breast cancer.
The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use current/emerging therapeutic strategies in the care of their patients with CLL/SLL.
The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with AML.
The management of cancer is constantly evolving through the introduction of new advances related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care.
The treatment of hematologic malignancies has become increasingly complex as a result of the rapid pace and number of advances in the biology and treatment of hematologic malignancies and the numerous novel drugs that have been approved or are in development, many with novel mechanisms of action.
The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data, expert recommendations, and guidelines to optimize the use of immuno-oncology–based combinations in the care of their patients with RCC.
Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies.
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current best practices in the treatment of AML.
Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC
Facebook
Twitter
LinkedIn
Forward